TransCode Therapeutics has created a platform of RNA drug candidates with the objective of improving patient outcomes.
Our lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has been shown to be responsible for the majority of all cancer deaths annually.
Currently we are continuing research on a variety of both diagnostic and therapeutic approaches targeting biomarkers broadly prevalent across numerous tumor types.
Advancing a Pipeline of First-in-Class RNA Therapeutic Candidates
Additionally, TransCode’s other drug candidates, TTX-siPDL1, 64Cu-TTX-MC138, TTX-siLIN28b, TTX-RIGA, TTX-CRISPR and TTX-mRNA, focus on treating cancer using RNA technology made possible through our proprietary delivery platform.
TTX is an investigational platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics which remain in development. Their safety and efficacy have not yet been evaluated by the FDA or any other regulatory agency.